FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121508812> ?p ?o ?g. }

• W3121508812 endingPage "339" @default.
• W3121508812 startingPage "339" @default.
• W3121508812 abstract "339 Background: Immunotherapy, including anti-PD-1 inhibitor, represents a promising breakthrough treatment in poor prognostic cancers such as biliary tract cancer (BTC). However, subset of pts suffer from unexpected acceleration of tumor growth following the initiation of immunotherapy, termed hyperprogressive disease (HPD). We assessed HPD in BTC pts treated with anti-PD-1 inhibitor in association with clinicopathologic features. Methods: This retrospective study included pts with BTC who were treated with pembrolizumab 200mg IV as palliative second or third line treatment in 4 tertiary hospitals in South Korea. Previous proposed tumor dynamic parameters including time to treatment failure (TTF), tumor growth kinetics (TGK) and tumor growth rate (TGR) were calculated per RECIST v1.1. Neural network modeling technique was adopted to find clinicopathologic features that can predict HPD. Results: Total of 223 pts with BTC were treated with palliative second or third line pembrolizumab between December 2015 to August 2020. ORR was 11.2% (n=1 for CR, n=24 for PR, n=70 for SD, n=118 for PD, and 10 pts not evaluable). Among patients with best response as PD (n=118), 41 patients (18.4% from total pts) met the criteria for HPD definition (>2-fold increase in both TGK and TGR in the experimental period compared to the reference period). HPD pts had worse prognosis compared to non-HPD pts in terms of TTF (median 1.4 vs 2.7 months, P =<0.0001) and OS (median 3.57 vs 5.27 months, P =0.03). Clinicopathologic features including age, ECOG performance status, primary tumor site, pathology, metastatic organ, previous treatment history (surgery or radiotherapy), pretreatment PD-L1 score, tumor markers, and baseline laboratory results (LDH, albumin, or neutrophil-to-lymphocyte ratio) did not predict HPD (compared to non-HPD pts or PD without HPD pts). By neural network modeling and plotting with hidden vectors, we could define HPD-high-risk cluster (n=37) and HPD-lower-risk cluster (n=80). Higher CA 19-9-to-lymphocyte ratio ( P =0.0004) or higher platelet-to-PD-L1 CPS (combined positivity score) ratio ( P =0.002) predicted HPD-high-risk-cluster. HPD pts (n=41) tend to have progression due to liver (73.2% vs 45.6%, P =0.0026) or peritoneum (53.7% vs 21.4%, P=<0.0001) metastases, compared to non-HPD pts (n=182). Conclusions: This study for the first time describe the clinicopathologic features of HPD among pembrolizumab treated BTC pts. Baseline pathology and laboratory tests may help optimal patient selection for immunotherapy to avoid HPD in BTC pts. Further validation of BTC-specific HPD predictive features and definition (TGK or TGR ratio cut-off) will be presented after comparison with clinicopathologic features among second line 5FU-based chemotherapy treated BTC pts." @default.
• W3121508812 created "2021-02-01" @default.
• W3121508812 creator A5000850685 @default.
• W3121508812 creator A5005245624 @default.
• W3121508812 creator A5010037501 @default.
• W3121508812 creator A5039472076 @default.
• W3121508812 creator A5049113012 @default.
• W3121508812 creator A5063234359 @default.
• W3121508812 creator A5066759908 @default.
• W3121508812 creator A5071354146 @default.
• W3121508812 creator A5071819927 @default.
• W3121508812 creator A5090754319 @default.
• W3121508812 date "2021-01-20" @default.
• W3121508812 modified "2023-10-16" @default.
• W3121508812 title "Characterization of hyperprogressive disease in patients with advanced biliary tract cancer treated with anti-PD-1 inhibitor: A multicenter retrospective study." @default.
• W3121508812 doi "https://doi.org/10.1200/jco.2021.39.3_suppl.339" @default.
• W3121508812 hasPublicationYear "2021" @default.
• W3121508812 type Work @default.
• W3121508812 sameAs 3121508812 @default.
• W3121508812 citedByCount "0" @default.
• W3121508812 crossrefType "journal-article" @default.
• W3121508812 hasAuthorship W3121508812A5000850685 @default.
• W3121508812 hasAuthorship W3121508812A5005245624 @default.
• W3121508812 hasAuthorship W3121508812A5010037501 @default.
• W3121508812 hasAuthorship W3121508812A5039472076 @default.
• W3121508812 hasAuthorship W3121508812A5049113012 @default.
• W3121508812 hasAuthorship W3121508812A5063234359 @default.
• W3121508812 hasAuthorship W3121508812A5066759908 @default.
• W3121508812 hasAuthorship W3121508812A5071354146 @default.
• W3121508812 hasAuthorship W3121508812A5071819927 @default.
• W3121508812 hasAuthorship W3121508812A5090754319 @default.
• W3121508812 hasConcept C121608353 @default.
• W3121508812 hasConcept C126322002 @default.
• W3121508812 hasConcept C141071460 @default.
• W3121508812 hasConcept C167135981 @default.
• W3121508812 hasConcept C2777701055 @default.
• W3121508812 hasConcept C2778822529 @default.
• W3121508812 hasConcept C2779134260 @default.
• W3121508812 hasConcept C2780057760 @default.
• W3121508812 hasConcept C2780258809 @default.
• W3121508812 hasConcept C3017919176 @default.
• W3121508812 hasConcept C71924100 @default.
• W3121508812 hasConcept C90924648 @default.
• W3121508812 hasConceptScore W3121508812C121608353 @default.
• W3121508812 hasConceptScore W3121508812C126322002 @default.
• W3121508812 hasConceptScore W3121508812C141071460 @default.
• W3121508812 hasConceptScore W3121508812C167135981 @default.
• W3121508812 hasConceptScore W3121508812C2777701055 @default.
• W3121508812 hasConceptScore W3121508812C2778822529 @default.
• W3121508812 hasConceptScore W3121508812C2779134260 @default.
• W3121508812 hasConceptScore W3121508812C2780057760 @default.
• W3121508812 hasConceptScore W3121508812C2780258809 @default.
• W3121508812 hasConceptScore W3121508812C3017919176 @default.
• W3121508812 hasConceptScore W3121508812C71924100 @default.
• W3121508812 hasConceptScore W3121508812C90924648 @default.
• W3121508812 hasIssue "3_suppl" @default.
• W3121508812 hasLocation W31215088121 @default.
• W3121508812 hasOpenAccess W3121508812 @default.
• W3121508812 hasPrimaryLocation W31215088121 @default.
• W3121508812 hasRelatedWork W2888624906 @default.
• W3121508812 hasRelatedWork W2916953213 @default.
• W3121508812 hasRelatedWork W2956079834 @default.
• W3121508812 hasRelatedWork W2970048128 @default.
• W3121508812 hasRelatedWork W3028346127 @default.
• W3121508812 hasRelatedWork W3040873953 @default.
• W3121508812 hasRelatedWork W3088565841 @default.
• W3121508812 hasRelatedWork W3106982287 @default.
• W3121508812 hasRelatedWork W3118379984 @default.
• W3121508812 hasRelatedWork W3215387979 @default.
• W3121508812 hasVolume "39" @default.
• W3121508812 isParatext "false" @default.
• W3121508812 isRetracted "false" @default.
• W3121508812 magId "3121508812" @default.
• W3121508812 workType "article" @default.